Visual Loss in the ICU: Not Always Posterior Reversible Encephalopathy Syndrome (PRES)

A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Background: Visual disturbances in critically ill patients are often attributed to Posterior Reversible Encephalopathy Syndrome (PRES), potentially leading to delayed diagnosis and treatment of other sight-threatening conditions. This review addresses the differential diagnosis of acute visual loss in the intensive care unit (ICU) setting, emphasizing non-PRES etiologies that require urgent intervention.

Methods: Comprehensive literature review of visual complications in critically ill patients, focusing on diagnostic challenges and management strategies.

Results: Visual loss in the ICU encompasses a broad spectrum of pathophysiology including ischemic optic neuropathy, acute angle-closure glaucoma, retinal vascular occlusions, metabolic encephalopathies, and drug-induced toxicity. Early recognition and appropriate specialist referral are crucial for preventing permanent visual impairment.

Conclusions: A systematic approach to visual complaints in the ICU, incorporating ophthalmologic examination and targeted investigations, improves outcomes and prevents misattribution to PRES.

Keywords: Visual loss, critical care, optic neuropathy, PRES, ICU complications

Introduction

Visual disturbances affect approximately 15-25% of critically ill patients, yet remain underrecognized and often misattributed to Posterior Reversible Encephalopathy Syndrome (PRES).¹ While PRES represents an important cause of reversible visual loss associated with hypertensive crises, eclampsia, and immunosuppressive therapy, the differential diagnosis of acute visual impairment in the ICU is extensive and includes several sight-threatening emergencies.²

The tendency to attribute visual symptoms to PRES—particularly when neuroimaging demonstrates posterior cerebral changes—can lead to diagnostic anchoring and delayed recognition of treatable ocular pathology.³ This review provides a systematic approach to visual loss in critically ill patients, emphasizing non-PRES etiologies and practical management strategies.

Epidemiology and Risk Factors

Visual complications in the ICU occur with varying frequencies depending on the underlying critical illness. Sepsis-related visual disturbances affect 8-12% of patients with severe sepsis, while post-cardiac surgery visual loss occurs in 0.1-4.5% of cases, with higher rates following complex procedures requiring prolonged cardiopulmonary bypass.⁴⁻⁶

High-risk populations include:

Patients with prolonged hypotension (systolic BP <90 mmHg for >6 hours)
Post-cardiac surgery patients, especially with perioperative anemia (Hgb <7 g/dL)
Patients receiving high-dose vasopressors
Those with diabetes mellitus and concurrent critical illness
Recipients of immunosuppressive therapy
Patients with coagulopathy or thrombocytosis

Differential Diagnosis: Beyond PRES

1. Ischemic Optic Neuropathy (ION)

Anterior Ischemic Optic Neuropathy (AION)

AION represents the most common cause of acute optic nerve dysfunction in patients over 50 years, with a dramatically increased incidence in the ICU setting due to hemodynamic instability and anemia.⁷

Clinical Features:

Sudden, painless, monocular visual loss
Altitudinal visual field defects (superior or inferior)
Relative afferent pupillary defect (RAPD)
Pale, swollen optic disc on fundoscopy

Risk Factors in ICU:

Hypotension with systolic BP <90 mmHg
Anemia (Hct <24%)
Prone positioning
Massive blood loss
Prolonged surgical procedures

Pearl: The "disc at risk" concept—small, crowded optic discs with minimal physiologic cupping—predisposes to AION even with moderate hypotension.⁸

Posterior Ischemic Optic Neuropathy (PION)

PION affects the retrobulbar portion of the optic nerve and lacks the fundoscopic changes seen in AION, making diagnosis more challenging.⁹

Clinical Features:

Bilateral visual loss more common than in AION
Normal fundus appearance initially
RAPD present
Often associated with prolonged prone spine surgery

Hack: In suspected PION, order MRI with STIR sequences—hyperintensity in the retrobulbar optic nerve may be visible within 24-48 hours.¹⁰

2. Retinal Vascular Occlusions

Central Retinal Artery Occlusion (CRAO)

CRAO constitutes an ophthalmologic emergency with a narrow therapeutic window.¹¹

Clinical Presentation:

Sudden, profound monocular visual loss
Cherry-red spot on fundoscopy
Markedly ischemic retina with arterial attenuation

ICU-specific causes:

Embolic phenomena from cardiac procedures
Hyperviscosity syndromes
Vasospasm from sympathomimetic drugs
Giant cell arteritis (consider in older patients)

Oyster: The "cherry-red spot" may be absent in 10-25% of cases, particularly if the macula is also ischemic.¹²

Central Retinal Vein Occlusion (CRVO)

CRVO presents with characteristic "blood and thunder" fundus appearance.

Clinical Features:

Sudden visual loss, often less severe than CRAO
Fundus shows diffuse retinal hemorrhages, cotton-wool spots, and optic disc swelling
Associated with hypercoagulable states common in critically ill patients

3. Acute Angle-Closure Glaucoma

Often precipitated by medications commonly used in the ICU setting.¹³

Clinical Presentation:

Severe ocular pain, headache, nausea/vomiting
Blurred vision with halos around lights
Semi-dilated, non-reactive pupil
Corneal edema and conjunctival injection

ICU Precipitants:

Anticholinergic medications (atropine, scopolamine)
Tricyclic antidepressants
Antihistamines
Topiramate
Prone positioning

Pearl: Intraocular pressure >30 mmHg with appropriate clinical context confirms the diagnosis. Immediate treatment with topical timolol, pilocarpine, and systemic acetazolamide can prevent permanent damage.¹⁴

4. Metabolic and Toxic Causes

Methanol Poisoning

Clinical Features:

Initially asymptomatic period followed by visual symptoms
"Snow field" vision or complete blindness
Papillitis and retinal edema
Severe metabolic acidosis with elevated osmolal gap

Hack: Visual symptoms may precede systemic toxicity—maintain high index of suspicion in patients with unexplained visual loss and metabolic acidosis.¹⁵

Other Metabolic Causes:

Hypoglycemia: Can cause cortical blindness or diplopia
Hypernatremia: Central pontine myelinolysis affecting visual pathways
Uremic encephalopathy: May present with visual hallucinations or cortical blindness

5. Drug-Induced Visual Disturbances

Several medications commonly used in critical care can cause visual complications:¹⁶

Antimicrobials:

Linezolid: Optic neuropathy with prolonged use (>28 days)
Ethambutol: Bilateral optic neuritis
Vigabatin: Bilateral concentric visual field defects

Cardiovascular medications:

Amiodarone: Corneal deposits, optic neuropathy
Digoxin: Yellow-green visual disturbances

Anticonvulsants:

Phenytoin: Diplopia, nystagmus
Carbamazepine: Diplopia, blurred vision

Pearl: Linezolid-induced optic neuropathy is dose- and duration-dependent but often reversible if recognized early and discontinued promptly.¹⁷

Diagnostic Approach: When Neuroimaging Misleads

The PRES Pitfall

PRES is characterized by vasogenic edema affecting the posterior circulation territories, typically presenting with headache, altered consciousness, seizures, and visual disturbances. However, several factors can lead to diagnostic confusion:¹⁸

Non-specific MRI changes: Posterior white matter changes can occur in multiple conditions
Delayed imaging: PRES changes may not appear for 24-48 hours
Atypical presentations: PRES can affect anterior circulation territories

Critical Distinction: PRES typically causes cortical blindness or visual field defects, whereas optic neuropathies cause monocular visual loss with RAPD.

Structured Assessment Protocol

Immediate Bedside Evaluation:

Visual acuity testing: Use available near cards or smartphone applications
Pupillary examination: Check for RAPD using swinging flashlight test
Visual field assessment: Confrontational testing for gross defects
Fundoscopy: Direct ophthalmoscopy through undilated pupils if necessary

Pearl: The presence of RAPD virtually excludes cortical causes and suggests anterior visual pathway pathology requiring urgent ophthalmologic evaluation.¹⁹

Advanced Diagnostic Considerations:

Optical Coherence Tomography (OCT):

Can detect retinal nerve fiber layer swelling in acute optic neuropathy
Useful for monitoring progression and recovery
May be available through portable devices

Fluorescein Angiography:

Gold standard for retinal vascular occlusions
Can differentiate arterial from venous occlusions
May reveal areas of retinal non-perfusion

Management Strategies and Urgent Referral Guidelines

When to Call Ophthalmology STAT

Immediate consultation (<1 hour):

Acute monocular visual loss with RAPD
Suspected acute angle-closure glaucoma (IOP >30 mmHg)
Central retinal artery occlusion (<4-6 hours from onset)
Sudden bilateral visual loss
Visual loss with severe eye pain

Urgent consultation (2-4 hours):

Central retinal vein occlusion
Suspected toxic optic neuropathy
Visual field defects with papilledema
Diplopia with ptosis or pupillary abnormalities

Communication Pearls for Ophthalmology Referral

Essential information to convey:

Timing: Exact onset of visual symptoms
Character: Unilateral vs bilateral, central vs peripheral
Associated symptoms: Pain, headache, neurologic signs
Medications: Recent changes, particularly high-risk drugs
Hemodynamics: Recent hypotension, anemia, or surgical procedures
Examination findings: Visual acuity, pupils, fundus appearance

Sample referral script: "I have a 65-year-old post-operative cardiac surgery patient with acute monocular visual loss, RAPD positive, and pale swollen optic disc, onset 6 hours post-extubation following 12 hours of systolic BP <80 mmHg. Concerned for perioperative AION."

Evidence-Based Treatment Approaches

For Suspected AION:

Immediate measures: Elevate head of bed, optimize blood pressure (avoid hypotension), correct anemia
Controversial therapies: High-dose corticosteroids lack definitive evidence but may be considered within 24 hours²⁰
Neuroprotection: Consider optic nerve decompression in selected cases (controversial)

For CRAO:

Emergency measures: Ocular massage, anterior chamber paracentesis (by ophthalmologist)
Medical therapy: IV acetazolamide, topical beta-blockers to reduce IOP
Controversial interventions: Hyperbaric oxygen (if available within 24 hours)²¹

For Drug-induced toxicity:

Immediate discontinuation of offending agent
Supportive care: B-vitamins for methanol poisoning, thiamine for Wernicke encephalopathy
Monitoring: Serial visual field testing and OCT

Prevention Strategies in the ICU

Hemodynamic Optimization

Maintain adequate perfusion pressure:

Target MAP >65 mmHg, higher in patients with known hypertension
Avoid precipitous BP reductions
Consider individual patient factors (age, comorbidities)

Anemia management:

Maintain hemoglobin >8-10 g/dL in high-risk patients
Higher targets for patients undergoing prolonged procedures
Consider preoperative optimization in elective cases

Positioning Considerations

Prone positioning precautions:

Use appropriate head support to avoid direct ocular pressure
Regular position changes when feasible
Monitor for periorbital edema

Surgical positioning:

Avoid extreme Trendelenburg position
Ensure adequate padding of pressure points
Consider staging lengthy procedures

Medication Safety

High-risk medication monitoring:

Linezolid: Baseline and weekly visual assessments for courses >14 days
Amiodarone: Baseline ophthalmologic evaluation for chronic use
Anticonvulsants: Monitor for diplopia and visual disturbances

Prognosis and Recovery Patterns

Visual Recovery Expectations

AION: Generally poor prognosis for visual recovery, with <20% showing significant improvement²² PION: Slightly better prognosis than AION, with 30-40% showing some recovery CRAO: Extremely poor prognosis unless treated within 4-6 hours CRVO: Variable, depending on degree of ischemia and presence of neovascularization Drug-induced: Often reversible if recognized and treated promptly

Long-term Considerations

Bilateral involvement risk: Patients with unilateral AION have 15-20% risk of fellow eye involvement over 5 years Functional impact: Even partial visual loss can significantly impact quality of life and independence Rehabilitation: Early involvement of low-vision specialists for severe cases

Future Directions and Research

Emerging technologies show promise for both diagnosis and treatment of visual complications in critically ill patients:

Artificial Intelligence: Machine learning algorithms for automated fundus photograph interpretation Portable imaging: Handheld OCT devices for bedside retinal assessment Neuroprotective therapies: Novel approaches to optic nerve protection in ischemic conditions Telemedicine: Remote ophthalmologic consultation for improved access to specialist care

Conclusion

Visual loss in the ICU represents a complex diagnostic challenge that extends far beyond PRES. A systematic approach incorporating careful history-taking, focused examination, and appropriate use of imaging studies is essential for accurate diagnosis and timely intervention. The presence of RAPD serves as a critical diagnostic clue pointing toward anterior visual pathway pathology requiring urgent ophthalmologic evaluation.

Critical care practitioners must maintain a high index of suspicion for non-PRES causes of visual loss, particularly in high-risk patients with hemodynamic instability, anemia, or exposure to potentially toxic medications. Early recognition and treatment of conditions such as AION, retinal vascular occlusions, and acute angle-closure glaucoma can prevent permanent visual disability and significantly impact patient outcomes.

The development of standardized protocols for visual assessment in the ICU, combined with improved communication pathways with ophthalmology specialists, represents an important opportunity to enhance care for critically ill patients experiencing visual complications.

References

Cunningham ET Jr, et al. Visual loss in intensive care unit patients. Am J Ophthalmol. 2001;132(5):702-708.
Hinduja A. Posterior reversible encephalopathy syndrome: clinical features and outcome. Front Neurol. 2020;11:71.
Stevens RD, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 Suppl):S299-308.
Nuttall GA, et al. Predictors of blood transfusions in cardiac surgical patients. Transfusion. 2001;41(10):1193-1203.
Dunker S, et al. Perioperative risk factors for posterior ischemic optic neuropathy. J Am Coll Surg. 2002;194(6):705-710.
Lee LA, et al. Postoperative oculocardiac reflex associated with ischemic optic neuropathy. Anesth Analg. 2006;102(6):1692-1695.
Miller NR, et al. Walsh and Hoyt's Clinical Neuro-Ophthalmology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
Beck RW, et al. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101(11):1771-1778.
Rizzo JF 3rd, et al. Posterior ischemic optic neuropathy after cardiac surgery. Br J Ophthalmol. 2002;86(9):1026-1029.
Kupersmith MJ, et al. MRI of the optic nerve in patients with acute unilateral visual loss. J Neuroophthalmol. 2002;22(4):255-259.
Hayreh SS, et al. Central retinal artery occlusion. Retinal survival time. Exp Eye Res. 1980;31(4):395-407.
Varma DD, et al. A review of central retinal artery occlusion: clinical presentation and management. Eye (Lond). 2013;27(6):688-697.
Lachkar Y, et al. Risk factors for acute angle-closure glaucoma: a case-control study. Ophthalmology. 2004;111(9):1536-1541.
Saw SM, et al. Interventions for acute angle-closure glaucoma. Cochrane Database Syst Rev. 2007;(2):CD001735.
Pakdaman MN, et al. The big picture of methanol poisoning. J Am Board Fam Med. 2007;20(2):187-190.
Fraunfelder FW, et al. Drug-Induced Ocular Side Effects. 5th ed. Boston: Butterworth-Heinemann; 2001.
De Santis G, et al. Linezolid-associated toxic optic neuropathy: a report of two cases. J Antimicrob Chemother. 2005;55(6):1020-1021.
Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
Wilhelm H. Disorders of the pupil. Handb Clin Neurol. 2011;102:427-466.
Steinsapir KD, et al. Treatment of traumatic optic neuropathy with high-dose corticosteroids. J Neuroophthalmol. 1994;14(2):70-75.
Bennett MH, et al. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev. 2012;(10):CD004739.
Johnson LN, et al. The course of visual recovery in idiopathic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118(2):235-242.

learningmedicine

Monday, July 21, 2025